Systemic administration of polyamines (spermine or spermidine) restored strong IK1 rectification, prolonged the QT interval, and significantly reduced arrhythmia inducibility in a mouse model of Short QT Syndrome type 3.
Does systemic polyamine administration reduce arrhythmia inducibility and prolong QT interval in a mouse model of Short QT Syndrome type 3?
Systemic polyamine administration restores normal electrophysiology and reduces arrhythmia inducibility in a mouse model of Short QT Syndrome type 3, suggesting a potential targeted therapy.
Short QT Syndrome type 3 (SQTS3) is an inherited disorder marked by an abnormally short QT interval on ECG and a high risk of life-threatening arrhythmias, for which effective targeted therapies are lacking. SQTS3 is caused by Kir2.1 mutations that enhance the outward component of the strong inward rectifier potassium current (IK1), disrupting its normal voltage-dependent regulation and severely abbreviating the cardiac action potential. Using a mouse model of SQTS3 carrying the Kir2.1M301K mutation, we examine whether administration of polyamines, the fundamental blockers of Kir2.1 channels, could restore the normal QT interval and prevent arrhythmia. Male mutant mice display reduced IK1 rectification, reduced sodium channel function, QT interval shortening, and a high susceptibility to induced ventricular tachycardia. Here, we show that systemic polyamine administration restores strong IK1 rectification, rescues sodium current density, prolongs action potential duration and QT interval, and significantly reduces arrhythmia inducibility, identifying a potential therapeutic approach for SQTS, a life-threatening disease. Short QT Syndrome type 3 is a rare genetic disorder where excessive potassium current shortens the heart’s electrical cycle, increasing the risk of sudden death. Here, the authors show that polyamines-based treatment restores normal heart rhythms and prevents lethal arrhythmias in a disease model.
Recent publication in high-impact journal; mechanistic insight into rare arrhythmia syndrome generating expert discussion in cardiology communities.
Moreno-Manuel et al. (Sat,) conducted a other in Short QT Syndrome type 3 (SQTS3). Polyamines (spermine and spermidine) vs. Untreated mutant mice and wild-type controls was evaluated on QT interval and arrhythmia inducibility. Systemic administration of polyamines (spermine or spermidine) restored strong IK1 rectification, prolonged the QT interval, and significantly reduced arrhythmia inducibility in a mouse model of Short QT Syndrome type 3.